Changes in the brain vessels in patients with non-alcoholic fatty liver disease and carbohydrate metabolism disorder

Ye.S. Sirchak, V.I. Griga, N.Yu. Kurchak, A.Yu. Kutsenko


Background. The studies of brain vessels in patients with non-alcoholic fatty liver disease (NAFLD) can reveal new aspects of early detection of cerebral hemodynamic disorders, and will also allow the identification of a high-risk patients group. The purpose was to investigate the peculiarities of changes in the brain vessels in patients with NAFLD in combination with insulin resistance (IR) or type 2 diabetes mellitus (T2DM). Materials and methods. The study involved 74 patients with NAFLD (34 patients with non-alcoholic fatty hepatosis (NAFH) and 40 patients with non-alcoholic steatohepatitis (NASH)). The comparison group included 38 patients (16 patients with IR and 22 patients with T2DM). The condition of the blood flow in the brain was studied using ultrasound duplex scan of the extracranial portion of the common carotid artery (eCCA), the external carotid artery (eCA), the extracranial portion of the internal carotid artery, middle cerebral artery, the vertebral artery (VA), ophthalmic artery. The peak systolic velocity (PSV) and the time-average maximum (TAMX) of blood flow velocity in the studied vessels was determined. Results. The asymmetric damage to the vessels of the brain with more severe left ventricular dysfunction with NAFH is conspicuous; it is more pronounced in patients with the NASH stage, especially in combination with IR. Hemodynamically, the most significant changes were found in eCCA, namely, the decrease in PSV was found to be 38.1 ± 2.3 cm/s on the right, and 36.6 ± 3.4 cm/s on the left, TAMX reduction 20.4 ± 2.1 cm/s on the right, and 16.7 ± 1.8 cm/s on the left. Conclusions. The patients with NAFLD, as well as IR and T2DM had a decrease in the speed of blood flow in extracranial vessels of the brain, mainly in the eCCA, eCA and VA (segment 3). The most pronounced blood flow deficiency has been observed in patients with NASH in combination with IR, mainly on the left, especially in еCCA.


non-alcoholic fatty liver disease; insulin resistance; type 2 diabetes mellitus; brain vessels

Full Text:



Carr RM, Oranu A, Khungar V. Non-alcoholic fatty liver disease: Pathophysiology and management. Gastroenterol Clin North Am. 2016 Dec;45(4):639-652. doi: 10.1016/j.gtc.2016.07.003.

Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis. 2018 Feb;22(1):39-57. doi: 10.1016/j.cld.2017.08.008.

Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018 Aug 23;6(4):451-462. doi: 10.1016/j.jcmgh.2018.07.004.

Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 2017 Apr 14;9(4). pii: E387. doi: 10.3390/nu9040387.

Stepanov YuM, Nedzvetskaya NV, Yagmur VB, Klenina IA. Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease. Gastroenterologia. 2018;52(1):13-18. doi: 10.22141/2308-2097.52.1.2018.130772. (in Ukrainian).

Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013 Aug 28;218(3):R25-36. doi: 10.1530/JOE-13-0201.

Zheng C, Zhenqi L. Vascular function, insulin action and exercise: an intricate interplay. Trends Endocrinol Metab. 2015 Jun;26(6):297-304. doi: 10.1016/j.tem.2015.02.002.

Hwang MH, Lee S. Insulin resistance: vascular function and exercise. Integr Med Res. 2016 Sep;5(3):198-203. doi: 10.1016/j.imr.2016.06.001.

VanWagner LB, Terry JG, Chow LS, et al. Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: The CARDIA study. Obesity (Silver Spring). 2017 Mar;25(3):642-651. doi: 10.1002/oby.21767.

World Health Organization. Global Database on Body Mass Index (BMI). Available from:

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

Gul'chij MV, Matjuha LF, Netjazhenko VZ, et al. Cukrovyj diabet 2 typu: adaptovana klinichna nastanova, zasnovana na dokazah [Type 2 diabetes mellitus: adapted clinical evidence-based guideline]. Kyiv; 2012. 343 p. (in Ukrainian).

Filipović B, Marković O, Đurić V, Filipović B. Сognitive Changes and Brain Volume Reduction in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol. 2018 Feb 27;2018:9638797. doi: 10.1155/2018/9638797.

Rasool A, Dar W, Latief M, Dar І, Sofi N, Khan MA. Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. Brain Circ. 2017 Jan-Mar;3(1):35-40. doi: 10.4103/bc.bc_28_16.

Lee JE, Lee YJ, Chung SY, Cho HW, Park BJ, Jung DH. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men. PLoS One. 2018 Mar 22;13(3):e0193191. doi: 10.1371/journal.pone.0193191.

Airaghi L, Rango M, Maira D, et al. Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis. 2018 Jan;268:27-31. doi: 10.1016/j.atherosclerosis.2017.11.012.

Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта